News & Media
News Updates
Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surges NEW YORK, May 15, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the
20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended
Workplace drug testing protects employee well-being, reduces operational risk, and supports compliance. Testing programs must combine legal awareness with ethical responsibility to be effective and respected. As global attitudes toward
Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people Multilingual rollout aligns with product readiness and accelerates international sales pipeline development NEW YORK, May
In high-risk industries like construction, logistics, transport, manufacturing, and mining, the consequences of drug and alcohol misuse extend far beyond the individual. Even a single incident involving an impaired worker
Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets Latin American drug screening market projected to reach USD 1.1 billion by
Testing for illicit drug use has been readily available since the 1960s. Initially, those suspected of drug use would be required to submit a blood, hair, urine, or saliva sample
Discover how the Intelligent Fingerprinting Drug Testing Solution works via our easy-to-follow fingerprint drug testing demo. The Intelligent Fingerprinting Drug Screening System is quick and easy to use, detecting commonly
Integration of Arabic opens opportunities in the Middle East and supports Company’s strategic global expansion goals NEW YORK, March 31, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or
INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach $448 million by 2030 Major Spanish accounts currently require 1,000 drug testing cartridges per month NEW YORK,
Company’s 6th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology Patent protection strengthens Company’s competitive position as it prepares for planned entry into multi-billion dollar
NEW YORK, March 25, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today provided shareholders with a
Media Contact
For media enquiries, please contact marketing@ibs.inc.
Featured Media
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. Our innovative technology has been featured worldwide in leading news outlets and media platforms.
The Intelligent Fingerprinting Drug Screening System is revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis.
